biostudies-literatureZhao QMinistry of Science and Technology of the People's Republic of China (MOST)Guangdong Provincial Key Laboratory of Construction Foundation ()Guangzhou Municipal Science and Technology Bureau (GZST)Guangdong Special Support Plan ()Sun Yat-sen University (SYSU)3886-3896https://www.ebi.ac.uk/biostudies/studies/S-EPMC12434392biostudies-literatureUnknown31(18)<h4>Purpose</h4>This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)-T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV-hepatocellular carcinoma after liver transplantation.<h4>Patients and methods</h4>In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV-TCR-T cells (mRNA-HBV-TCR-T cells) and (ii) one to three infusions of lentiviral-transduced HBV-TCR-T cells (lenti-HBV-TCR-T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor efficClinical cancer research : an official journal of the American Association for Cancer ResearchHBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation.PMC12434392R070152023YFF15012002020B12120600262024A04J63888247068782404650R700042024B03J1235Y-2023-7562023YFF150120282270686Li JKoh STan HGuo ZHuang JQin MWai LEDan JLiu ZZhao QWang THe XLuo WWong RWJfalseHBV-Specific TCR-T Cell Therapy Combining mRNA Electroporation and Lentiviral Transduction: Treatment Regimen for Recurrent HBV-Related HCC after Liver Transplantation.<h4>Purpose</h4>This study aimed to preliminarily evaluate the safety, tolerability, and antitumor efficacy of hepatitis B virus (HBV)-specific T-cell receptor (TCR)-T cell therapy combining mRNA electroporation and lentiviral transduction in patients with recurrent HBV-hepatocellular carcinoma after liver transplantation.<h4>Patients and methods</h4>In this pilot study (NCT04677088), two types of autologous HBV-specific TCR-redirected T cells were assessed without prior lymphodepletion: (i) multiple infusions of mRNA-electroporated HBV-TCR-T cells (mRNA-HBV-TCR-T cells) and (ii) one to three infusions of lentiviral-transduced HBV-TCR-T cells (lenti-HBV-TCR-T cells). Treatment-related adverse events were assessed using the Common Terminology Criteria for Adverse Events, and antitumor effic2025-01-01T00:00:00Z2025 Sep2026-06-02T05:27:32.858Z2026-04-14T03:14:17.377ZS-EPMC124343924070507910.1158/1078-0432.CCR-25-1245